Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Chemotherapy

NEPA—a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting

Nature Reviews Clinical Oncology volume 11, page 377 (2014)Cite this article

Subjects

Nausea and vomiting are two of the most common adverse effects of many cancer treatments and are especially associated with chemotherapy. The risk of chemotherapy-induced nausea and vomiting (CINV) varies based on the type of treatment received and on several external factors. Some chemotherapy regimens, such as cisplatin, are highly emetogenic (HEC) with an high incidence of CINV (>90%), whereas others are moderately emetogenic (MEC) with a 30–90% incidence of nausea and vomiting.

CINV has a multifactorial origin, involving several neurotransmitters and receptors. Antiemetic guidelines recommend the use of combination regimens—over several days—to prevent and control CINV; however, adherence to such guidelines is suboptimal and many patients remain undertreated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gralla, R. J. et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann. Oncol. 10.1093/annonc/mdu096

  2. Hesketh, P. J. et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann. Oncol. 10.1093/annonc/mdu110

  3. Aapro, M. A. et al. Randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. 10.1093/annonc/mdu101

Download references

Authors
  1. Alessia Errico
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Errico, A. NEPA—a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting. Nat Rev Clin Oncol 11, 377 (2014). https://doi.org/10.1038/nrclinonc.2014.92

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.92

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing